ArticlePeerJ2025
A propensity score-matched retrospective study on sacubitril/valsartan use and 6-month readmission rates in patients with acute heart failure.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sacubitril/valsartan is a compound preparation commonly used for treating chronic heart failure with reduced ejection fraction. In clinical practice, it is also administered to patients with newly diagnosed acute heart failure. However, limited research exists on its benefits during hospitalization in this patient population. Aim: To investigate the impact of in-hospital use of sacubitril/valsartan on the 6-month readmission rate in patients with newly diagnosed acute heart failure. Method: A retrospective study was conducted involving 176 patients admitted for the first time with acute heart failure at Xiaoshan Hospital Affiliated to Hangzhou Normal University. Patients were divided into two groups based on whether they received sacubitril/valsartan during hospitalization: a treatment group and a control group. Clinical data were collected, and propensity score matching (PSM) was used to balance baseline characteristics. Logistic regression analysis was performed to evaluate the effect of sacubitril/valsartan on 6-month readmission. Results: After PSM, 53 matched pairs were obtained, with balanced covariates between the two groups. Before matching, the readmission rate was 10.47% in the treatment group and 25.56% in the control group. Multivariate logistic regression indicated that sacubitril/valsartan was associated with a reduced risk of readmission (OR = 0.339, 95% CI [0.116-0.994], Conclusions: In-hospital use of sacubitril/valsartan does not significantly reduce the risk of 6-month readmission in patients with newly diagnosed acute heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.